BCL2A1 and acute myeloid leukemia: The results demonstrated that BCL2A1 was significantly upregulated in most tumors, including GBM and LGG, and downregulated in lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), liver hepatocellular carcinoma (LIHC), Wilms tumor (WT), acute myeloid leukemia (LAML) and acute lymphoblastic leukemia (ALL).